$EGRX Market Cap: $11.69 Million
Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue
$257.6M
TTM
Gross Margin
70.86%
TTM
Net Earnings
$11.95M
TTM
Current Assets
$187.3M
Q2 2023
Current Liabilities
$86.63M
Q2 2023
Current Ratio
216.15%
Q2 2023
Total Assets
$404.8M
Q2 2023
Total Liabilities
$152.8M
Q2 2023
Book Value
$252.0M
Q2 2023
Cash
$15.35M
Q2 2023
P/E
0.9783
Dec 02, 2024 EST
Free Cash Flow
-$9.392M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Revenue $316.6M $171.5M $187.8M $195.9M $213.3M $236.7M $189.5M $66.23M $19.10M $13.68M $2.539M $9.500M
YoY Change 84.56% -8.66% -4.13% -8.17% -9.88% 24.92% 186.11% 246.76% 39.62% 438.76% -73.27%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Revenue $316.6M $171.5M $187.8M $195.9M $213.3M $236.7M $189.5M $66.23M $19.10M $13.68M $2.539M $9.500M
Cost Of Revenue $94.94M $31.53M $33.65M $47.89M $42.37M $33.71M $35.79M $15.65M $11.71M $7.381M $3.166M $1.800M
Gross Profit $221.7M $140.0M $154.2M $135.0M $151.4M $203.0M $153.7M $50.58M $7.385M $6.298M -$627.0K $7.700M
Gross Profit Margin 70.01% 81.62% 82.08% 68.91% 70.97% 85.76% 81.11% 76.37% 38.67% 46.04% -24.69% 81.05%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Selling, General & Admin $106.6M $75.32M $78.60M $76.37M $60.51M $71.42M $53.33M $20.17M $9.326M $4.958M $6.399M $4.600M
YoY Change 41.56% -4.17% 2.92% 26.21% -15.27% 33.92% 164.46% 116.22% 88.1% -22.52% 39.11%
% of Gross Profit 48.1% 53.79% 50.99% 56.57% 39.97% 35.18% 34.7% 39.87% 126.28% 78.72% 59.74%
Research & Development $34.09M $51.28M $30.79M $36.81M $44.42M $32.61M $28.29M $27.86M $16.82M $9.795M $12.81M $8.700M
YoY Change -33.52% 66.56% -16.37% -17.13% 36.23% 15.26% 1.56% 65.65% 71.68% -23.51% 47.18%
% of Gross Profit 15.38% 36.62% 19.97% 27.27% 29.34% 16.06% 18.41% 55.07% 227.7% 155.53% 112.99%
Depreciation & Amortization $646.0K $764.0K $872.0K $972.0K $1.155M $932.0K $641.0K $112.0K $104.0K $135.0K $240.0K $270.0K
YoY Change -15.45% -12.39% -10.29% -15.84% 23.93% 45.4% 472.32% 7.69% -22.96% -43.75% -11.11%
% of Gross Profit 0.29% 0.55% 0.57% 0.72% 0.76% 0.46% 0.42% 0.22% 1.41% 2.14% 3.51%
Operating Expenses $140.7M $126.6M $109.4M $113.2M $176.7M $162.7M $136.1M $63.67M $37.86M $22.13M $22.37M $13.30M
YoY Change 11.15% 15.74% -3.35% -35.95% 8.59% 19.53% 113.82% 68.18% 71.03% -1.05% 68.2%
Operating Profit $80.96M $2.769M $32.95M $21.82M $36.62M $73.99M $53.35M $2.560M -$18.76M -$8.455M -$19.83M -$5.600M
YoY Change 2823.8% -91.6% 51.06% -40.42% -50.51% 38.69% 1984.02% -113.65% 121.85% -57.36% 254.13%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Interest Expense -$3.774M $1.635M $2.577M $2.686M $2.736M $1.136M $8.000K $11.00K $8.000K $309.0K $91.00K $0.00
YoY Change -330.83% -36.55% -4.06% -1.83% 140.85% 14100.0% -27.27% 37.5% -97.41% 239.56%
% of Operating Profit -4.66% 59.05% 7.82% 12.31% 7.47% 1.54% 0.01% 0.43%
Other Income/Expense, Net -$15.75M -$7.317M -$10.28M $183.0K -$2.578M -$1.045M $76.00K $14.00K -$515.0K $1.508M -$333.0K $0.00
YoY Change 115.29% -28.8% -5715.85% -107.1% 146.7% -1475.0% 442.86% -102.72% -134.15% -552.85%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Pretax Income $61.43M -$4.548M $22.68M $22.00M $34.04M $72.95M $53.43M $2.574M -$19.27M -$6.947M -$20.16M -$5.500M
YoY Change -1450.77% -120.06% 3.09% -35.37% -53.34% 36.53% 1975.64% -113.36% 177.41% -65.55% 266.62%
Income Tax $25.79M $4.079M $10.69M $7.685M $2.135M $21.00M -$28.03M $3.000K -$1.295M -$899.0K -$781.0K -$400.0K
% Of Pretax Income 41.98% 47.13% 34.93% 6.27% 28.79% -52.46% 0.12%
Net Earnings $35.64M -$8.627M $11.99M $14.31M $31.90M $51.94M $81.45M $2.571M -$17.98M -$6.048M -$19.38M -$5.200M
YoY Change -513.14% -171.96% -16.24% -55.14% -38.58% -36.23% 3068.14% -114.3% 197.24% -68.8% 272.75%
Net Earnings / Revenue 11.26% -5.03% 6.38% 7.31% 14.96% 21.94% 42.99% 3.88% -94.13% -44.21% -763.41% -54.74%
Basic Earnings Per Share $2.76 -$0.66 $0.89 $1.04 $2.16 $3.44 $5.24 $0.17 -$1.97 -$3.25
Diluted Earnings Per Share $2.73 -$0.66 $0.87 $1.01 $2.09 $3.27 $4.96 $0.16 -$1.97 -$3.25 -$1.396M -$374.1K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Cash & Short-Term Investments $55.32M $97.66M $103.2M $109.8M $78.80M $114.7M $52.80M $79.10M $42.70M $10.50M $6.600M $12.60M
YoY Change -43.35% -5.37% -6.01% 39.34% -31.3% 117.23% -33.25% 85.25% 306.67% 59.09% -47.62%
Cash & Equivalents $55.32M $97.66M $103.2M $109.8M $78.80M $114.7M $52.80M $79.10M $22.70M $10.50M $5.100M $8.100M
Short-Term Investments $0.00 $20.00M $0.00 $1.500M $4.500M
Other Short-Term Assets $13.20M $11.89M $3.700M $15.10M $10.30M $15.10M $11.40M $1.900M $1.700M $1.900M $600.0K $800.0K
YoY Change 11.02% 221.35% -75.5% 46.6% -31.79% 32.46% 500.0% 11.76% -10.53% 216.67% -25.0%
Inventory $47.79M $21.91M $8.100M $6.600M $8.300M $5.100M $2.700M $15.00M $1.300M $0.00 $100.0K $1.100M
Prepaid Expenses
Receivables $72.44M $41.15M $51.10M $48.00M $66.50M $53.80M $42.20M $26.30M $7.300M $5.100M $1.600M $300.0K
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $188.8M $172.6M $166.1M $179.4M $163.8M $188.7M $109.1M $122.3M $53.00M $17.50M $8.900M $14.80M
YoY Change 9.36% 3.92% -7.41% 9.52% -13.2% 72.96% -10.79% 130.75% 202.86% 96.63% -39.86%
Property, Plant & Equipment $1.168M $1.636M $2.100M $5.900M $2.400M $6.800M $3.300M $2.200M $300.0K $400.0K $500.0K $700.0K
YoY Change -28.61% -22.1% -64.41% 145.83% -64.71% 106.06% 50.0% 633.33% -25.0% -20.0% -28.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $52.88M $29.08M $32.40M $13.90M $14.50M $11.50M $28.80M $100.0K $0.00 $200.0K $100.0K $100.0K
YoY Change 81.86% -10.26% 133.09% -4.14% 26.09% -60.07% 28700.0% -100.0% 100.0% 0.0%
Total Long-Term Assets $217.4M $81.13M $87.10M $75.20M $74.80M $81.40M $105.2M $2.300M $400.0K $600.0K $500.0K $800.0K
YoY Change 167.99% -6.86% 15.82% 0.53% -8.11% -22.62% 4473.91% 475.0% -33.33% 20.0% -37.5%
Total Assets $406.2M $253.7M $253.2M $254.6M $238.6M $270.1M $214.3M $124.6M $53.40M $18.10M $9.400M $15.60M
YoY Change
Accounts Payable $18.99M $16.43M $6.300M $5.500M $9.900M $27.00M $15.70M $3.900M $4.100M $1.200M $1.400M $1.500M
YoY Change 15.59% 160.81% 14.55% -44.44% -63.33% 71.97% 302.56% -4.88% 241.67% -14.29% -6.67%
Accrued Expenses $85.84M $32.34M $23.80M $28.40M $23.50M $15.40M $23.50M $23.90M $9.700M $3.100M $1.300M $1.800M
YoY Change 165.46% 35.87% -16.2% 20.85% 52.6% -34.47% -1.67% 146.39% 212.9% 138.46% -27.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $8.600M $0.00
YoY Change -100.0%
Long-Term Debt Due $6.250M $25.61M $8.000M $5.000M $6.300M $4.900M
YoY Change -75.59% 220.09% 60.0% -20.63% 28.57%
Total Short-Term Liabilities $111.1M $74.38M $38.10M $38.80M $39.70M $47.30M $41.00M $34.30M $20.30M $14.30M $20.90M $9.300M
YoY Change 49.36% 95.21% -1.8% -2.27% -16.07% 15.37% 19.53% 68.97% 41.96% -31.58% 124.73%
Long-Term Debt $56.22M $0.00 $25.10M $33.60M $38.20M $42.90M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -100.0% -25.3% -12.04% -10.96%
Other Long-Term Liabilities $5.297M $2.903M $4.000M $3.000M $0.00 $700.0K $22.10M $0.00 $1.700M $700.0K $0.00
YoY Change 82.47% -27.43% 33.33% -100.0% -96.83% -100.0% 142.86%
Total Long-Term Liabilities $61.51M $2.903M $29.10M $36.60M $38.20M $43.60M $22.10M $0.00 $0.00 $1.700M $700.0K $0.00
YoY Change 2018.95% -90.02% -20.49% -4.19% -12.39% 97.29% -100.0% 142.86%
Total Liabilities $172.6M $77.28M $67.20M $75.40M $77.80M $90.90M $63.10M $34.30M $20.30M $16.00M $21.50M $9.300M
YoY Change 123.35% 15.0% -10.88% -3.08% -14.41% 44.06% 83.97% 68.97% 26.88% -25.58% 131.18%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Basic Shares Outstanding 12.93M shares 13.05M shares 13.48M shares 13.75M shares 14.77M shares 15.10M shares 15.53M shares 15.25M shares 9.956M shares 3.044M shares
Diluted Shares Outstanding 13.07M shares 13.05M shares 13.77M shares 14.14M shares 15.28M shares 15.91M shares 16.43M shares 16.25M shares 9.956M shares 3.044M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $11.688 Million

About EAGLE PHARMACEUTICALS, INC.

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.

Industry: Pharmaceutical Preparations Peers: Aerovate Therapeutics, Inc. ALBIREO PHARMA, INC. Humacyte, Inc. ALX ONCOLOGY HOLDINGS INC Arcturus Therapeutics Holdings Inc. Celularity Inc CytoDyn Inc. Ocugen, Inc. MeiraGTx Holdings plc